ZHAW Life Sciences and Facility Management, Grüentalstrasse 14, 8820 Wädenswil(PDF 3,0 MB)
We are delighted to be one of the main sponsors at the 13th Day of Life Sciences on 9th June 2022. Register for the symposium ‘Competencies in Drug Discovery’ by 7th June, we look forward to seeing you there! Day of Life Sciences | ZHAW Life Sciences and Facility Management
RGCC Network doctors from across the world set their alarm clocks and tuned in for RGCC’s first ever virtual RGCC Gathering on 24th-26 September. Broadcasting live from the beautiful lakeside city of Zug, the event treated virtual guests to more than 23 hours of lectures and presentations delivered by RGCC’s very own scientists. Doctors from […]
Treatment protocol for cancer with unknown origin of the primary tumor
14th October 2020
On October 14th, RGCC’s director and members of his team, hosted an online-webinar about RGCC’s tests, and therapies. Participants had also the opportunity to watch real-time, the administration of therapies on an experimental model.
On September 19th, 2020, we welcomed clinicians from the wider area. Dr. Papasotiriou and the members of the Research and Development Department presented the workflow they follow, including Cells Isolation, Targets Identification and Validation, Small Molecular Weight molecules production, Monoclonal Antibodies production as well as Pharmaceutical formulation of all products. At the final part, clinicians […]
Integrative Oncology | RGCC founder and genetics pioneer Dr Ioannis Papasotiriou hosted a two-day symposium in Melbourne, Australia. Take a look at the range of subjects we covered at the gathering and hear from some of the delegates who took part.
On January 2020 took place the in Tokyo the Clinical CTC Seminar. This event was promoted by Dr. Atsushi Yanagisawa, Chairman of the Intravenous Therapy Study Group and Dr. Kunihiro Kitamura, Director of the Kitamura Clinic in Fukuoka. Dr. Ioannis Papasotiriou was one of the basics lecturer.
Can brain tumours also be tested with a blood sample?
No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
Which test is the most comprehensive test?
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
How do online consultations work?
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs. The online consultation will be available via the Cancer A-Z app soon… please keep checking the app for updates.
Will online consultations take place via Zoom, Skype or another method?
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.